| Date | Title | Description |
| 12.08.2024 | Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update | - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 -
- ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed -
- Recent Key Opinion Leader W... |
| 12.03.2024 | Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | - Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 -
- Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® -
- Strengthened Capital Position from Registered Direct Equ... |
| 12.03.2024 | Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | - |
| 07.02.2024 | Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering | - |
| 14.08.2023 | Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update | - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open -
- Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings -
- Man... |
| 21.12.2021 | Clearside Biomedical : CLSD-CLS-AX OASIS Results Slide Presentation | OASIS Phase 1/2a Clinical Trial Safety Results December 21, 2021
Forward-Looking Statements
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words &quo... |
| 16.08.2021 | Arctic Vision : Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India | SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biom... |
| 16.08.2021 | Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India | SHANGHAI, Aug. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biom... |
| 15.08.2021 | Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India | |
| 28.04.2016 | Clearside Biomedical, Inc. to Present Data on Suprachoroidal Drug Administration at 2016 ARVO Meeting | ALPHARETTA, Ga.–(BUSINESS WIRE)–April 28, 2016–
Clearside Biomedical, Inc. today announced four poster presentations associated with suprachoroidal drug administration will be presented at the 2016 Annual Meeting of the Association for Rese... |
| 26.04.2016 | Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion | Patients receiving a single treatment of ZUPRATA™ together with EYLEA® qualified for 60% fewer additional EYLEA retreatments over a 3-month period (p=0.013)
Patients in the ZUPRATA + EYLEA arm achieved 19 letters of improvement in Best Corr... |
| 29.02.2016 | Clearside Biomedical, Inc. Announces Appointment of Richard J. Croarkin to the Board of Directors | ALPHARETTA, Ga.–(BUSINESS WIRE)–February 29, 2016–
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that R... |
| 08.01.2016 | Clearside Biomedical, Inc. Files Registration Statement for Proposed Initial Public Offering | ALPHARETTA, Ga.–(BUSINESS WIRE)–January 8, 2016–
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that it ... |
| 05.01.2016 | Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis | Clinical Trial Achieves Statistical Significance on Primary Efficacy Endpoint
ALPHARETTA, Ga.–(BUSINESS WIRE)–January 5, 2016–
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class ... |
| 14.12.2015 | Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration | ALPHARETTA, Ga.–(BUSINESS WIRE)–December 14, 2015–
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced comple... |
| 08.12.2015 | Clearside Biomedical gets $20M for drug-device combo for blindness disorders | Clearside has three clinical trials for macular edema underway using CLS-TA, its proprietary formulation of the steroidal drug triamcinolone acetonide that’s been developed to work with the company’s microinjector. It’s enrolling patients w... |
| 07.12.2015 | Clearside Biomedical, Inc. Enrolls First Patient in Phase 3 Clinical Trial of CLS-TA Using Suprachoroidal Drug Administration | First Patient Randomized in Six-Month Efficacy Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis
ALPHARETTA, Ga.–(BUSINESS WIRE)–December 7, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical ... |
| 03.12.2015 | Clearside Biomedical Closes $20M Series C Financing | Clearside Biomedical, Inc., an Alpharetta, GA-based clinical-stage biopharmaceutical company developing drug therapies to treat blinding diseases of the eye, closed a $20m Series C financing.
Backers included new investors Aju IB Investment... |
| 03.12.2015 | Clearside Biomedical, Inc. Completes $20 Million Series C Financing | ALPHARETTA, Ga.–(BUSINESS WIRE)–December 3, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the closing ... |
| 12.11.2015 | Clearside Biomedical, Inc. Announces Fifth Patent Issued in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices | ALPHARETTA, Ga.–(BUSINESS WIRE)–November 12, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the U.S. Pa... |
| 12.10.2015 | Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space (SCS™) Drug Administration | For the Treatment of Macular Edema Associated with Non-Infectious Uveitis
ALPHARETTA, Ga.–(BUSINESS WIRE)–October 12, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug the... |
| 24.09.2015 | Clearside Biomedical, Inc. Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration | Major Milestone for Innovative Ophthalmic Drug Administration Platform
ALPHARETTA, Ga.–(BUSINESS WIRE)–September 24, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug ther... |
| 22.09.2015 | Clearside Biomedical, Inc. to Present at the 13th Congress of International Ocular Inflammation Society (IOIS) in San Francisco, CA | Hosted by the Foster Ocular Immunology Society (FOIS)
ALPHARETTA, Ga.–(BUSINESS WIRE)–September 22, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies uniquely positioned to... |
| 09.07.2015 | Clearside Biomedical, Inc. to Present at International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical Meeting | ALPHARETTA, Ga.–(BUSINESS WIRE)–July 9, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced Glenn Noronha, PhD, executi... |
| 16.06.2015 | Clearside Biomedical, Inc. Announces Favorable End-of-Phase 2 Review with the FDA | Plans to initiate a Phase 3 clinical study for the treatment of macular edema associated with non-infectious uveitis using proprietary administration through the suprachoroidal space (SCS) of the eye
ALPHARETTA, Ga.–(BUSINESS WIRE)–June 16,... |
| 04.05.2015 | Clearside Biomedical, Inc. and Santen, Inc. Announce Research Collaboration in Glaucoma | Expands Previous Research Collaboration to Include 2nd Largest Ophthalmic Market
ALPHARETTA, Ga. & EMERYVILLE, Calif.–(BUSINESS WIRE)–May 4, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-i... |
| 30.04.2015 | Clearside Biomedical, Inc. to Report Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide at 2015 ARVO Meeting | ALPHARETTA, Ga.–(BUSINESS WIRE)–April 30, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their P... |
| 22.04.2015 | Clearside Biomedical, Inc. Announces Purchase of iScience Patent Portfolio for Suprachoroidal Space Drug Delivery | ALPHARETTA, Ga.–(BUSINESS WIRE)–April 22, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the purchase and acquisit... |
| 16.03.2015 | Clearside Biomedical, Inc. Reports Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide | Patients Treated in the Clinical Trial Exhibited Improvement in Best Corrected Visual Acuity No Meaningful Increases in IOP Observed; No Patient Required IOP-lowering Medication
ALPHARETTA, Ga.–(BUSINESS WIRE)–March 16, 2015–
Clearside Biom... |
| 02.03.2015 | Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion | Follows the recent initiation of Clearside’s Phase 2 clinical trial for the treatment of macular edema associated with non-infectious uveitis
ALPHARETTA, Ga.–(BUSINESS WIRE)–March 2, 2015–
Clearside Biomedical, Inc., a clinical-stage biopha... |
| 05.01.2015 | Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial For the Treatment of Macular Edema Associated With Non-Infectious Uveitis | ALPHARETTA, Ga.–(BUSINESS WIRE)–January 5, 2015–
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the fi... |
| 15.10.2014 | Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis | ALPHARETTA, Ga.–(BUSINESS WIRE)–October 15, 2014–
Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis.
In the phase 1/2 clinical study, eight patients diagnosed with non-inf... |
| 02.09.2014 | Clearside Biomedical Lands $16M in Series B |
ALPHARETTA, GA, Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing.
>> Click here for more funding data on Clearside Biomedical
>> To export Clearside Biomedical funding data to PDF a... |
| 02.09.2014 | Clearside Biomedical Closes $16M Series B Financing | Clearside Biomedical, Inc., an Alpharetta, GA-based clinical-stage biopharmaceutical company, closed a $16m Series B financing.
Backers included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Ph... |
| 18.02.2013 | Ophthalmology startup uses microneedles for targeted delivery of drugs for retinal diseases | According to a statement from the company, the funding came from Santen Inc., the California-based subsidiary of Santen Pharmaceuticals Co., Ltd in Japan, and other investors including Mountain Group Capital, Hatteras Venture Partners, Geor... |
| 20.02.2012 | Eye treatments firm Clearside close to $4M raise for microneedle technology | Clearside is developing a novel drug-delivery platform for the eyes. Right now, doctors can deliver drugs to the eye by means of what’s called in intravitreal injection. But Clearside’s microneedle technology aims to deliver drugs and prote... |
| 15.02.2012 | Pharmas, medical device makers set to pitch at CED Life Science conference | A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or... |
| 06.01.2012 | Clearside Biomedical Launches with $4M Series A Venture Financing | Clearside Biomedical, an Atlanta, GA-based ophthalmic startup specializing in the research, development and commercialization of therapeutic products through a proprietary ocular microinjection platform that targets the individual compartme... |
| 05.01.2012 | Clearside Biomedical Launched with $4M Series A |
ATLANTA, GA, Ophthalmic startup Clearside Biomedical and Hatteras Venture Partners announced that they have launched the company with a $4,000,000 Series A venture financing.
>> Click here for more funding data on Clearside Biomedi... |
| 05.01.2012 | Clearside raises $4M for targeted drug delivery system and new eye drug | Clearside will direct the investment toward development of its novel microinjection drug delivery platform. The company’s microneedle technology allows for delivery of drugs and proteins to the retina and other hard to access parts of the e... |
| - | Pharmas, medical device makers set to pitch at CED Life Science conference | Life science companies and investors, let’s make a deal.
The annual CED Life Science Conference kicks off in Raleigh, North Carolina today where small drug developers hope to make the right connection with a big pharmaceutical company or ve... |
| - | Ophthalmology startup uses microneedles for targeted delivery of drugs for retinal diseases | A one-year-old company using drug delivery to improve ophthalmic drugs is raising fresh capital to support trials of its microinjection platform.
Clearside Biomedical has raised $7.9 million and could continue raising up to $8.5 million, ac... |
| - | Clearside raises $4M for targeted drug delivery system and new eye drug | Ophthalmic startup Clearside Biomedical has launched with a $4 million initial round of investment for the company to continue R&D on its lead drug candidate and a novel drug delivery system that could administer that drug in hard to ac... |
| - | Clearside Biomedical gets $20M for drug-device combo for blindness disorders | Clearside Biomedical just closed a $20 million C round to further clinical work on its drug-device combination that treats a range of vision disorders.
Investors include Aju IB Investment, Cormorant asset Management, Perceptive Advisors, Sp... |
| - | Eye treatments firm Clearside close to $4M raise for microneedle technology | Ophthalmic treatments company Clearside Biomedical is nearly finished raising its $4 million first round of financing.
The Georgia company, which has its research and development operations in Durham, North Carolina, launched its series A r... |
